5-Amino-1MQvsTesofensine

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytoplasmic enzyme that is significantly overexpressed in white adipose tissue of obese individuals. NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) using S-adenosyl methionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosyl homocysteine. This reaction effectively depletes two critical metabolic cofactors — NAD+ precursors and SAM — from fat cells.

By inhibiting NNMT, 5-Amino-1MQ preserves the cellular pools of both nicotinamide (which feeds NAD+ biosynthesis via the salvage pathway) and SAM (the universal methyl donor required for hundreds of methylation reactions). Increased NAD+ availability activates sirtuin enzymes (particularly SIRT1 and SIRT3), which are master regulators of cellular metabolism — they deacetylate and activate PGC-1alpha (promoting mitochondrial biogenesis), enhance fatty acid oxidation, and suppress lipogenic gene expression. The net effect is that adipocytes shift from a fat-storing to a fat-burning metabolic state.

In preclinical models, NNMT inhibition reduced adipocyte size, decreased total body fat mass, and increased energy expenditure without affecting food intake — suggesting the weight loss mechanism is primarily metabolic rather than appetite-driven. Additionally, NNMT inhibition has shown improvements in insulin sensitivity and reductions in plasma cholesterol. However, all published efficacy data comes from cell culture and rodent studies; no human clinical trials have been completed, so the translational relevance remains uncertain.

Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that simultaneously blocks the presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT). Originally developed by NeuroSearch as NS2330 for neurodegenerative diseases, it was repurposed for obesity after clinical trials for Alzheimer's and Parkinson's disease unexpectedly revealed significant weight loss in treated patients.

The weight loss mechanism involves all three monoamine systems working in concert. Serotonin (5-HT) reuptake inhibition increases serotonergic tone in the hypothalamic appetite centers, particularly the paraventricular nucleus and ventromedial hypothalamus. Elevated synaptic serotonin activates 5-HT2C receptors on POMC neurons, promoting the release of alpha-MSH, which activates MC4R and produces satiety. This is the same pathway targeted by lorcaserin (Belviq), but tesofensine adds two additional mechanisms. Norepinephrine reuptake inhibition activates alpha-1 and beta-adrenergic receptors in the lateral hypothalamus, reducing appetite and increasing sympathetic nervous system activity, which raises basal metabolic rate and thermogenesis.

The dopamine reuptake inhibition component may be the most important differentiator. By increasing dopamine availability in the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area), tesofensine may reduce the drive for food reward-seeking behavior — the compulsive eating of palatable, high-calorie foods that is mediated by dopamine signaling in the same circuits involved in addiction. This addresses a component of obesity that pure appetite suppressants miss: the hedonic (pleasure-driven) eating that overrides homeostatic satiety signals. Phase II clinical trials demonstrated remarkable efficacy — the 0.5 mg dose produced approximately 12.8 kg weight loss over 6 months, roughly double what GLP-1 receptor agonists typically achieve — though cardiovascular monitoring is necessary due to increases in heart rate associated with the noradrenergic and dopaminergic effects.